-
公开(公告)号：US20190040055A1
公开(公告)日：2019-02-07
申请号：US16157618
申请日：2018-10-11
Applicant: Pfizer Inc.
Inventor： Aaron Craig Burns , Michael Raymond Collins , Samantha Elizabeth Greasley , Robert Louis Hoffman , Peter Qinhua Huang , Robert Steven Kania , Pei-Pei Kung , Maria Angelica Linton , Lakshmi Sourirajan Narasimhan , Paul Francis Richardson , Daniel Tyler Richter , Graham Smith
IPC: C07D417/14 , C07D417/08 , C07D277/46 , A61K45/06 , A61K31/427 , A61K31/501 , A61K31/444 , A61K31/4439 , C07D401/14 , A61K31/506
Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein A, L, D, R1-R15, w, x, y, and z are defined herein. The novel cycloalkyl-linked diheterocycle derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.
-
公开(公告)号：US09133215B2
公开(公告)日：2015-09-15
申请号：US14156144
申请日：2014-01-15
Applicant: PFIZER INC.
Inventor： Simon Bailey , Benjamin Joseph Burke , Michael Raymond Collins , Jingrong Jean Cui , Judith Gail Deal , Robert Louis Hoffman , Qinhua Huang , Ted William Johnson , Robert Steven Kania , John Charles Kath , Phuong Thi Quy Le , Michele Ann McTigue , Cynthia Louise Palmer , Paul Francis Richardson , Neal William Sach
IPC: C07D273/02 , C07D413/04 , C07D413/14 , C07D491/08 , C07D491/18 , C07D498/08 , C07D498/18 , C07D498/22 , C07D513/18
CPC classification number: C07D498/08 , C07D273/02 , C07D413/04 , C07D413/14 , C07D491/08 , C07D491/18 , C07D498/18 , C07D498/22 , C07D513/18
Abstract: The invention relates to compounds of formula (Φ) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
Abstract translation: 本发明涉及本文进一步定义的式（Φ）化合物及其药学上可接受的盐，涉及包含这些化合物和盐的药物组合物及其用途。 本发明的化合物和盐抑制间变性淋巴瘤激酶（ALK）和/或EML4-ALK，并且可用于治疗或改善异常细胞增殖性疾病如癌症。
-
公开(公告)号：US20130252961A1
公开(公告)日：2013-09-26
申请号：US13786106
申请日：2013-03-05
Applicant: PFIZER INC.
Inventor： Simon BAILEY , Benjamin Joseph Burke , Michael Raymond Collins , Jingrong Jean Cui , Judith Gail Deal , Robert Louis Hoffman , Qinhua Huang , Ted William Johnson , Robert Steven Kania , John Charles Kath , Phuong Thi Quy Le , Michele Ann McTigue , Cynthia Louise Palmer , Paul Francis Richardson , Neal William Sach
IPC: C07D498/08 , C07D513/18 , C07D498/22 , C07D498/18 , C07D491/18
CPC classification number: C07D498/08 , C07D273/02 , C07D413/04 , C07D413/14 , C07D491/08 , C07D491/18 , C07D498/18 , C07D498/22 , C07D513/18
Abstract: The invention relates to compounds of formula (Φ) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
Abstract translation: 本发明涉及本文进一步定义的式（Phi）化合物及其药学上可接受的盐，涉及包含这些化合物和盐的药物组合物及其用途。 本发明的化合物和盐抑制间变性淋巴瘤激酶（ALK）和/或EML4-ALK，并且可用于治疗或改善异常细胞增殖性疾病如癌症。
-
公开(公告)号：US10676471B2
公开(公告)日：2020-06-09
申请号：US16416997
申请日：2019-05-20
Applicant: Pfizer Inc.
Inventor： Aaron Craig Burns , Michael Raymond Collins , Samantha Elizabeth Greasley , Robert Louis Hoffman , Peter Qinhua Huang , Robert Steven Kania , Pei-Pei Kung , Maria Angelica Linton , Lakshmi Sourirajan Narasimhan , Paul Francis Richardson , Daniel Tyler Richter , Graham Smith
IPC: C07D417/14 , C07D401/14 , C07D417/08 , A61K31/427 , A61K31/4439 , A61K31/444 , A61K31/501 , A61K31/506 , A61K45/06 , C07D277/46
Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein A, L, D, R1-R15, w, x, y, and z are defined herein. The novel cycloalkyl-linked diheterocycle derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.
-
公开(公告)号：US20190270737A1
公开(公告)日：2019-09-05
申请号：US16416997
申请日：2019-05-20
Applicant: Pfizer Inc.
Inventor： Aaron Craig Burns , Michael Raymond Collins , Samantha Elizabeth Greasley , Robert Louis Hoffman , Peter Qinhua Huang , Robert Steven Kania , Pei-Pei Kung , Maria Angelica Linton , Lakshmi Sourirajan Narasimhan , Paul Francis Richardson , Daniel Tyler Richter , Graham Smith
IPC: C07D417/14 , C07D417/08
Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein A, L, D, R1-R15, w, x, y, and z are defined herein. The novel cycloalkyl-linked diheterocycle derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.
-
Patent Agency Ranking
公开(公告)号：US20190040047A1
公开(公告)日：2019-02-07
申请号：US16156304
申请日：2018-10-10
Applicant: Pfizer Inc.
Inventor： Michael Raymond Collins , Robert Steven Kania , Robert Arnold Kumpf , Pei-Pei Kung , Daniel Tyler Richter , Scott Channing Sutton , Martin James Wythes
IPC: C07D405/14 , C07B59/00 , C07D409/14 , C07D401/06 , C07D401/14 , C07D413/14
Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
-
公开(公告)号：US20170298048A1
公开(公告)日：2017-10-19
申请号：US15635648
申请日：2017-06-28
Applicant: Pfizer Inc.
Inventor： Michael Raymond Collins , Robert Steven Kania , Robert Arnold Kumpf , Pei-Pei Kung , Daniel Tyler Richter , Scott Channing Sutton , Martin James Wythes
IPC: C07D405/14 , C07D401/06 , C07D401/14 , C07D409/14
CPC classification number: C07D405/14 , C07B59/002 , C07B2200/05 , C07D401/06 , C07D401/14 , C07D409/14 , C07D413/14
Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
-
公开(公告)号：US09593097B2
公开(公告)日：2017-03-14
申请号：US14968405
申请日：2015-12-14
Applicant: Pfizer Inc.
Inventor： Ted William Johnson , Paul Francis Richardson , Michael Raymond Collins , Daniel Tyler Richter , Benjamin Joseph Burke , Sacha Ninkovic , Ketan Satish Gajiwala , Maria Angelica Linton , Phuong Thi Quy Le , Jacqui Elizabeth Hoffman
IPC: C07D401/14 , C07D403/14 , A61K31/53 , A61K31/506 , A61K31/4523 , A61P35/00 , C07D405/14 , C07D471/04 , C07D487/04
CPC classification number: C07D401/14 , A61K31/4523 , A61K31/506 , A61K31/53 , C07D403/14 , C07D405/14 , C07D471/04 , C07D487/04
Abstract: Compounds of the general formula (I): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
Abstract translation: 通式（I）的化合物：这些化合物的制备方法，含有这些化合物的组合物，以及这些化合物的用途。
-
公开(公告)号：US20160176850A1
公开(公告)日：2016-06-23
申请号：US14968405
申请日：2015-12-14
Applicant: Pfizer Inc.
Inventor： Ted William Johnson , Paul Francis Richardson , Michael Raymond Collins , Daniel Tyler Richter , Benjamin Joseph Burke , Sacha Ninkovic , Ketan Satish Gajiwala , Maria Angelica Linton , Phuong Thi Quy Le , Jacqui Elizabeth Hoffman
IPC: C07D401/14 , C07D471/04 , C07D487/04 , C07D405/14
CPC classification number: C07D401/14 , A61K31/4523 , A61K31/506 , A61K31/53 , C07D403/14 , C07D405/14 , C07D471/04 , C07D487/04
Abstract: Compounds of the general formula (I): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
Abstract translation: 通式（I）的化合物：这些化合物的制备方法，含有这些化合物的组合物，以及这些化合物的用途。
-
公开(公告)号：US10570121B2
公开(公告)日：2020-02-25
申请号：US16156304
申请日：2018-10-10
Applicant: Pfizer Inc.
Inventor： Michael Raymond Collins , Robert Steven Kania , Robert Arnold Kumpf , Pei-Pei Kung , Daniel Tyler Richter , Scott Channing Sutton , Martin James Wythes
IPC: C07D401/06 , C07B59/00 , A61K31/4725 , C07D405/14 , C07D401/14 , C07D413/14 , C07D409/14
Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.025 seconds)
